Skip to main content
NewslettersWatchlist

Medicenna Therapeutics Corp(MDNA-T)
TSX

Today's Change
Real-Time Last Update
Day Low2.10
Day High2.17
Open:2.12
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX
GlobeNewswire
Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
GlobeNewswire
Medicenna Announces Results of Annual Meeting of Shareholders
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference
GlobeNewswire
Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference
GlobeNewswire
Medicenna Strengthens Board of Directors with Appointment of Karim Lalji
AI-generated - The Globe and Mail
Medicenna Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (MDNA)
GlobeNewswire
Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy
AI-generated - The Globe and Mail
Medicenna Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (MDNA)
GlobeNewswire
Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
GlobeNewswire
Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe
GlobeNewswire
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting
GlobeNewswire
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
GlobeNewswire
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum
AI-generated - The Globe and Mail
Medicenna Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (MDNA)
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
GlobeNewswire
Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
GlobeNewswire
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management

Profile

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.